FDA Inspection 951773 — Marshallton Capital Group
The FDA completed an inspection of Marshallton Capital Group on November 23, 2015 in Newark, DE. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 23, 2015
- Fiscal Year
- 2016
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Newark, DE (United States)